The American Heart Association will recognize Pradeep Natarajan, M.D., M.M.Sc., FAHA, with its 2026 Population Research Prize during Scientific Sessions 2026, to be held Nov. 6-9 in Chicago. The award, presented during the Presidential Session on Sunday, Nov. 8, honors his internationally recognized contributions to cardiovascular genetics and population research. As announced by NEWMEDIAWIRE, the prize highlights how human genetics and large-scale population studies are reshaping the understanding and prevention of cardiovascular disease.
Dr. Natarajan's research has uncovered genetic mechanisms in lipid disorders, coronary artery disease, and clonal hematopoiesis. He has advanced polygenic risk scores and precision medicine approaches that may identify individuals with elevated cardiovascular risk earlier in life. His discoveries have also accelerated the development of novel therapeutic targets. By integrating genomics, multi-omics, electronic health records, and large population biobanks, he has helped bridge genomic discovery with clinical application, advancing precision medicine while improving understanding of cardiovascular risk across diverse populations.
The implications of this recognition extend beyond a single career. Dr. Natarajan's work has been central to the Heart Association's scientific statements on polygenic risk scores for cardiovascular disease, direct-to-consumer genetic testing for cardiovascular disease, and the cardiovascular implications of clonal hematopoiesis. He also served on the writing committee for the 2026 Joint Clinical Practice Guideline on the Management of Dyslipidemia. These guidelines and statements are instrumental in translating genetic discoveries into everyday clinical practice, potentially leading to earlier interventions and more personalized treatment strategies.
"Congratulations to Dr. Pradeep Natarajan for his groundbreaking work that has redefined how human genetics and large population studies can be used to prevent cardiovascular disease," said Manesh R. Patel, M.D., FAHA, the American Heart Association's 2026-2027 volunteer president. "His innovative research has helped bridge genomic discovery with clinical application, advancing precision medicine while improving our understanding of cardiovascular risk across diverse populations."
Dr. Natarajan joined Amgen in August 2026 as vice president of global research, head of human genetics, and head of the Cardiometabolic Therapeutic Area. He also serves as a professor of medicine at Harvard Medical School and a distinguished physician at Massachusetts General Hospital. His career includes leadership of numerous NIH-funded investigations, over 330 peer-reviewed publications, and an $11.2 million NIH Common Fund project on somatic mosaicism. His mentorship of early-career investigators ensures that the next generation of cardiovascular genomics leaders will continue to drive innovation.
The Population Research Prize underscores the American Heart Association's commitment to funding and recognizing research that can lead to longer, healthier lives. As precision medicine moves from promise to practice, Dr. Natarajan's work exemplifies how genetic insights can inform prevention, diagnosis, and treatment. For more information about the American Heart Association's initiatives, visit heart.org or stroke.org.
